How Many Becton, Dickinson and Company (NYSE:BDX)’s Analysts Are Bullish?

Becton, Dickinson and Company (NYSE:BDX) Logo
Investors sentiment decreased to 1.1 in 2019 Q2. Its down 0.03, from 1.13 in 2019Q1. It worsened, as 49 investors sold Becton, Dickinson and Company shares while 364 reduced holdings. 103 funds opened positions while 353 raised stakes. 220.73 million shares or 3.04% less from 227.64 million shares in 2019Q1 were reported.
Lenox Wealth Mngmt invested in 0.04% or 481 shares. Lifeplan Gp accumulated 0.02% or 175 shares. Advisor Ltd Co, California-based fund reported 6,997 shares. Natixis Lp owns 28,219 shares. Daiwa Gp holds 11,018 shares. Page Arthur B holds 0.61% in Becton, Dickinson and Company (NYSE:BDX) or 2,935 shares. Reilly Advisors Ltd Liability, a California-based fund reported 750 shares. Zeke Capital Lc accumulated 4,703 shares. Fincl Consulate stated it has 0.14% in Becton, Dickinson and Company (NYSE:BDX). Rampart Investment Mgmt Communications Ltd Liability Corp holds 0.15% of its portfolio in Becton, Dickinson and Company (NYSE:BDX) for 5,030 shares. Hills Bank holds 15,634 shares or 1.02% of its portfolio. Condor Cap has 0.16% invested in Becton, Dickinson and Company (NYSE:BDX) for 4,083 shares. Winslow Evans Crocker Inc has 3,532 shares for 0.25% of their portfolio. Webster State Bank N A accumulated 2,513 shares or 0.09% of the stock. Guggenheim Capital Ltd Liability Corporation accumulated 45,036 shares or 0.09% of the stock.

Becton, Dickinson and Company (NYSE:BDX) Ratings Coverage

Among 4 analysts covering Becton (NYSE:BDX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Becton has $290 highest and $25000 lowest target. $275.20’s average target is 5.65% above currents $260.48 stock price. Becton had 11 analyst reports since March 19, 2019 according to SRatingsIntel. The stock of Becton, Dickinson and Company (NYSE:BDX) has “Buy” rating given on Friday, June 21 by Argus Research. On Monday, April 15 the stock rating was maintained by Barclays Capital with “Equal-Weight”. As per Tuesday, March 19, the company rating was maintained by Raymond James. The firm has “Outperform” rating given on Friday, September 6 by Wells Fargo. Below is a list of Becton, Dickinson and Company (NYSE:BDX) latest ratings and price target changes.

06/09/2019 Broker: Wells Fargo Rating: Outperform Old Target: $270.0000 New Target: $290.0000 Maintain
16/07/2019 Broker: Dickinson and Company Common Stock Rating: Morgan Stanley New Target: $250.0000 261.0000
28/06/2019 Broker: Dickinson and Company Common Stock Rating: Raymond James New Target: $265.0000 288.0000
21/06/2019 Broker: Argus Research Rating: Buy New Target: $290 Maintain
05/06/2019 Broker: BidaskScore Rating: Buy Upgrade
23/05/2019 Broker: BidaskScore Rating: Buy Upgrade
10/05/2019 Broker: Dickinson and Company Common Stock Rating: Keybanc New Target: $273.0000 262.0000
15/04/2019 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $260 New Target: $266 Maintain
21/03/2019 Broker: BidaskScore Rating: Buy Downgrade
19/03/2019 Broker: William Blair Rating: Buy Maintain

The stock decreased 0.64% or $1.67 during the last trading session, reaching $260.48. About 350,926 shares traded. Becton, Dickinson and Company (NYSE:BDX) has risen 2.24% since September 13, 2018 and is uptrending. It has outperformed by 2.24% the S&P500.

Becton, Dickinson and Company develops, makes, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company has market cap of $70.32 billion. It operates in two divisions, BD Medical and BD Life Sciences. It has a 91.14 P/E ratio. The BD Medical segment offers syringes, pen needles, and IV sets for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laproscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; and prefillable drug delivery systems.

More notable recent Becton, Dickinson and Company (NYSE:BDX) news were published by: Finance.Yahoo.com which released: “3 Dividend Aristocrats to Buy and Hold Forever – Yahoo Finance” on August 27, 2019, also Finance.Yahoo.com with their article: “Here is What Hedge Funds Think About Becton, Dickinson and Company (BDX) – Yahoo Finance” published on June 13, 2019, Finance.Yahoo.com published: “Is There Now An Opportunity In Becton, Dickinson and Company (NYSE:BDX)? – Yahoo Finance” on June 12, 2019. More interesting news about Becton, Dickinson and Company (NYSE:BDX) were released by: Finance.Yahoo.com and their article: “Should We Be Cautious About Becton, Dickinson and Company’s (NYSE:BDX) ROE Of 5.1%? – Yahoo Finance” published on July 29, 2019 as well as Finance.Yahoo.com‘s news article titled: “Would Becton, Dickinson and Company (NYSE:BDX) Be Valuable To Income Investors? – Yahoo Finance” with publication date: May 22, 2019.

Becton, Dickinson and Company (NYSE:BDX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.